Fan Meng-Ke, Qi Li-Li, Zhang Qi, Wang Ling
Department of Orthopedic Oncology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
Orthopedic Research Center, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
Cancer Manag Res. 2021 Jan 27;13:757-764. doi: 10.2147/CMAR.S285560. eCollection 2021.
Although the mortality rate of osteosarcoma (OS) patients has improved, there are still many unsolved problems concerning how to reduce recurrence and metastasis. In the tumor microenvironment, immune escape plays a more important role in tumor progression and development. Many costimulatory molecules of the B7 family have been reported to be involved in regulating immunological interactions between OS cells and immune cells. Among these molecules, B7-H1 and its receptor, programmed death-1 (PD-1), have been the focus of the fields of tumor immunology and have been recently applied in clinical trials of therapies for several solid tumors. These therapies, referred to as B7-H1/PD-1 checkpoint blockade therapies, are designed to block the interaction between the two molecules. Although the mechanism has been reported in some malignancies, the specific impact of B7-H1/PD-1 expression on OS has not been well defined. Here, we review the expression, function, and regulatory mechanism of the B7-H1/PD-1 axis in OS and introduce and compare the advantages and disadvantages of B7-H1/PD-1 immunotherapies in OS.
尽管骨肉瘤（OS）患者的死亡率有所改善，但在如何降低复发和转移方面仍存在许多未解决的问题。在肿瘤微环境中，免疫逃逸在肿瘤进展和发展中发挥着更重要的作用。据报道，B7家族的许多共刺激分子参与调节OS细胞与免疫细胞之间的免疫相互作用。在这些分子中，B7-H1及其受体程序性死亡蛋白1（PD-1）一直是肿瘤免疫学领域的研究重点，最近已应用于几种实体瘤的治疗临床试验。这些疗法被称为B7-H1/PD-1检查点阻断疗法，旨在阻断这两种分子之间的相互作用。尽管在一些恶性肿瘤中已经报道了其机制，但B7-H1/PD-1表达对OS的具体影响尚未明确界定。在此，我们综述了B7-H1/PD-1轴在OS中的表达、功能和调控机制，并介绍和比较了B7-H1/PD-1免疫疗法在OS中的优缺点。
